EU AI Act's Hidden Test: Pure Global on MedTech's New Rules

The EU's AI Act is creating a new, complex layer of regulation for MedTech companies, especially for those with AI-powered software. A device fully compliant with the Medical Device Regulation (MDR) could now be deemed a "high-risk AI system," demanding an entirely new set of evidence and documentation for market access. This episode of MedTech Global Insights explores this dual compliance challenge. We break down the specific new obligations the AI Act places on medical device manufacturers, from data governance to post-market surveillance, and discuss the significant business risks for companies that are not prepared for this regulatory intersection. Imagine your AI diagnostic tool, fully compliant with MDR, now faces a sales ban in the EU. Why? The new AI Act just reclassified it as 'high-risk,' and your existing documentation is suddenly obsolete. This is the hidden challenge facing innovators today. Key Takeaways: - How does the EU AI Act redefine risk for your medical software, separate from MDR? - What are the critical documentation gaps between your MDR technical file and AI Act requirements? - Why might your current data governance protocol fail the AI Act's strict standards? - How does the AI Act change what you need to monitor in your post-market surveillance plan? - What is the first step to assess if your SaMD falls into the "high-risk AI system" category? - How can you create a unified strategy to manage both MDR and AI Act compliance efficiently? - What specific human oversight measures are now mandatory for your AI device? - Are your current cybersecurity measures sufficient to ensure AI system robustness under the new law? For more information, contact us at [email protected] or visit https://pureglobal.com/. For FREE AI tools and a comprehensive medical device database, visit https://pureglobal.ai/.